GSK plc (GSK)
- Previous Close
45.07 - Open
45.31 - Bid 45.17 x 1000
- Ask 45.18 x 1800
- Day's Range
45.14 - 45.41 - 52 Week Range
33.33 - 45.41 - Volume
2,353,403 - Avg. Volume
3,233,732 - Market Cap (intraday)
92.409B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
16.61 - EPS (TTM)
2.72 - Earnings Date Jul 31, 2024
- Forward Dividend & Yield 1.50 (3.34%)
- Ex-Dividend Date May 16, 2024
- 1y Target Est
45.79
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
www.gsk.com70,212
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GSK
Performance Overview: GSK
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GSK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GSK
Valuation Measures
Market Cap
91.91B
Enterprise Value
109.04B
Trailing P/E
16.58
Forward P/E
11.47
PEG Ratio (5yr expected)
1.21
Price/Sales (ttm)
2.42
Price/Book (mrq)
5.32
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
14.59%
Return on Assets (ttm)
9.31%
Return on Equity (ttm)
38.78%
Revenue (ttm)
30.74B
Net Income Avi to Common (ttm)
4.48B
Diluted EPS (ttm)
2.72
Balance Sheet and Cash Flow
Total Cash (mrq)
4.1B
Total Debt/Equity (mrq)
134.34%
Levered Free Cash Flow (ttm)
5.63B
Research Analysis: GSK
Company Insights: GSK
GSK does not have Company Insights